Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta.
about
HCV NS3 protease enhances liver fibrosis via binding to and activating TGF-β type I receptorAdenoviral expression of a transforming growth factor-beta1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated ratsModern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targetsThrombospondin 1 acts as a strong promoter of transforming growth factor beta effects via two distinct mechanisms in hepatic stellate cellsCurrent status of novel antifibrotic therapies in patients with chronic liver diseaseLack of significant association of an insertion/deletion polymorphism in the angiotensin converting enzyme (ACE) gene with tropical calcific pancreatitis.Effects of Chinese traditional compound, JinSanE, on expression of TGF-beta1 and TGF-beta1 type II receptor mRNA, Smad3 and Smad7 on experimental hepatic fibrosis in vivo.LAP degradation product reflects plasma kallikrein-dependent TGF-β activation in patients with hepatic fibrosisSerum Inter-Alpha-Trypsin Inhibitor Heavy Chain 4 (ITIH4) in Children with Chronic Hepatitis C: Relation to Liver Fibrosis and Viremia.Preliminary experimental study of urethral reconstruction with tissue engineering and RNA interference techniques.Attenuation of CCl4-induced hepatic fibrosis in mice by vaccinating against TGF-β1Eicosapentaenoic acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient miceBiological Significance of Local TGF-β Activation in Liver Diseases.Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis.Targeted treatments for cirrhosis.Understanding the mechanism of hepatic fibrosis and potential therapeutic approachesInfluence of serum collected from rat perfused with compound Biejiaruangan drug on hepatic stellate cells.Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosisUtility of Translocator Protein (18 kDa) as a Molecular Imaging Biomarker to Monitor the Progression of Liver Fibrosis.Anti-TGF-beta strategies for the treatment of chronic liver disease.Emerging therapies for liver fibrosis.Effects of pentoxifylline on the hepatic content of TGF-beta1 and collagen in Schistosomiasis japonica mice with liver fibrosisThe anti-fibrotic effect of bone morphogenic protein-7(BMP-7) on liver fibrosisEmerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis.Membrane-anchored Serine Protease Matriptase Is a Trigger of Pulmonary Fibrogenesis.Matrix metalloproteinase gene delivery for liver fibrosisPancreatic stellate cells: new target in the treatment of chronic pancreatitis.Advances in antifibrotic therapy.Proteinase-activated receptor-2 transactivation of epidermal growth factor receptor and transforming growth factor-β receptor signaling pathways contributes to renal fibrosis.The antifibrotic effect of a serine protease inhibitor in the kidney.Depletion of β-arrestin2 in hepatic stellate cells reduces cell proliferation via ERK pathway.GFAP promoter-driven RNA interference on TGF-β1 to treat liver fibrosis.Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats.Fuzheng Huayu recipe prevents nutritional fibrosing steatohepatitis in mice.Liver fibrogenesis due to cholestasis is associated with increased Smad7 expression and Smad3 signaling.Targeted and regulable expression of transgenes in hepatic stellate cells and myofibroblasts in culture and in vivo using an adenoviral Cre/loxP system to antagonise hepatic fibrosis.TGF-beta1 gene silencing for treating liver fibrosis.Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy.Preventive effects of a fractioned polysaccharide from a traditional Chinese herbal medical formula (Yu Ping Feng San) on carbon tetrachloride-induced hepatic fibrosis.Signal transduction in alcohol-related diseases.
P2860
Q24308693-720CE8C8-AEE9-42B4-9FC2-2F3513AD0B8DQ24792944-20D57E25-1DD5-48CE-8CAC-2F27CDC84BD3Q28303698-139D3031-BC6C-4124-A8AB-1941268A4640Q28575592-31AD9268-6AFA-4347-978C-E0348F4E48E6Q30473375-7383F70C-6CBD-4F9D-8698-E717C908BCD6Q30828361-7C0CD5FC-68EE-4589-B180-23FA497B4291Q31158693-C0AC9053-E468-4121-B145-E76FB8D4DE4EQ33662935-D2910771-A7A8-43D0-BD7A-428A7193BEC9Q34256849-8B849936-F102-4F0C-BE64-F21651B6DC6EQ34642580-1C880363-58D0-40F4-A4AC-CB7F54ED263EQ35070050-49BFE1DD-AEC3-49AB-963A-B311CEEF4B7EQ35588868-FE237258-E03D-4900-9847-038B43B547E5Q35750103-A654692E-475C-4C24-8C7D-D78E19546025Q35781449-8EE93D7B-B924-4525-8116-F31E40EE0DF6Q35911123-9CDB31AD-C32A-481A-8EA0-0C0B6141723EQ36020916-EB2C0FFA-831E-431E-8E8C-C76133F245A1Q36308136-D1DE9D6C-3F3E-4A02-BBAD-B0073E59EB5BQ36308844-69581EA0-B046-4E45-B632-5F579FCCA94DQ36323627-A10395B3-4620-430A-9644-AF952BFD960BQ36339566-647BC927-0671-4A79-8C21-89F0DF039CC0Q36478124-1194DC76-E57C-43DE-925A-482FB33EACC3Q36506319-CCE20048-54F7-4C0C-87A9-A115D5C21F5FQ36663411-F8E6CBB4-778C-4424-9BB2-24EB16CB7B13Q36736835-2D431CFE-19E4-46F4-9986-7E11949DADEBQ36847591-72554938-6223-4496-AB0E-77AF0C33792FQ36852793-C1F8468A-8109-4A90-97BB-1F580D61CFD4Q36998028-D1CC3D17-337D-433D-AE82-53F54733BD23Q37353099-ED110420-1951-43A3-9D90-3D8F3CF08D66Q37415689-3BDE4041-77C9-49AC-A9EB-E07A7EC25646Q39148597-F59D46C8-E237-4472-BED4-2B54ED413B95Q39236344-AA6D9DEC-7AB6-4D51-8656-50088B877AB1Q39586742-15600E23-1375-43DB-8DE5-9AE4BE2B8914Q40204147-2276AFDB-7087-4C7B-9C11-D8EB5652AAB0Q41775019-50B62CC6-8F42-4DC9-A098-AD27CF1FB68AQ41890914-AECF4D22-9850-41F5-B2DA-23ACB89FE30DQ41943203-DD8F6EDB-AD90-4393-B7E8-CD2551549312Q42215330-2871244F-975B-4C4D-8094-867F50C9BD55Q42591676-9D54BE0A-CF9F-48C5-8174-5F34D4576E69Q42968161-0184C167-DD43-486B-9E25-31901F11D1A6Q46641842-61B73220-52F0-4703-9FE7-7D8004001C36
P2860
Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Prevention of rat hepatic fibr ...... generation of active TGF-beta.
@en
Prevention of rat hepatic fibr ...... generation of active TGF-beta.
@nl
type
label
Prevention of rat hepatic fibr ...... generation of active TGF-beta.
@en
Prevention of rat hepatic fibr ...... generation of active TGF-beta.
@nl
prefLabel
Prevention of rat hepatic fibr ...... generation of active TGF-beta.
@en
Prevention of rat hepatic fibr ...... generation of active TGF-beta.
@nl
P2093
P356
P1433
P1476
Prevention of rat hepatic fibr ...... generation of active TGF-beta.
@en
P2093
Moriwaki H
P304
P356
10.1053/GAST.2001.24832
P407
P577
2001-06-01T00:00:00Z